Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

350 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.
Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Hong L, et al. Among authors: vaporciyan aa. Nat Commun. 2023 Feb 8;14(1):695. doi: 10.1038/s41467-023-36328-z. Nat Commun. 2023. PMID: 36755027 Free PMC article.
A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients.
Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Vaporciyan AA, Watson TJ, Swisher SG; Members of the MD Anderson Esophageal Cancer Group and the University of Rochester School of Medicine and Dentistry Foregut Group. Gaur P, et al. Among authors: vaporciyan aa. Ann Surg. 2010 Oct;252(4):611-7. doi: 10.1097/SLA.0b013e3181f56419. Ann Surg. 2010. PMID: 20881767
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Pataer A, et al. Among authors: vaporciyan aa. J Thorac Oncol. 2012 May;7(5):825-32. doi: 10.1097/JTO.0b013e318247504a. J Thorac Oncol. 2012. PMID: 22481232 Free PMC article.
Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy.
Lopez Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Lopez Guerra JL, et al. Among authors: vaporciyan aa. Ann Oncol. 2013 Jan;24(1):67-74. doi: 10.1093/annonc/mds274. Epub 2012 Sep 20. Ann Oncol. 2013. PMID: 23002278 Free PMC article.
Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer.
Ball D, Mitchell A, Giroux D, Rami-Porta R; IASLC Staging Committee and Participating Institutions. Ball D, et al. J Thorac Oncol. 2013 Mar;8(3):315-21. doi: 10.1097/JTO.0b013e31827dc74d. J Thorac Oncol. 2013. PMID: 23334092 Free article.
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group. Hellmann MD, et al. Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6. Lancet Oncol. 2014. PMID: 24384493 Free PMC article. Review.
350 results